Technical Analysis for INMB - INmune Bio Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Historical INMB trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Multiple of Ten Bullish | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 50 DMA Support | Bullish | 4.08% | |
| Wide Bands | Range Expansion | 4.08% | |
| Up 3 Days in a Row | Strength | 4.08% | |
| Oversold Stochastic | Weakness | 4.08% | |
| Crossed Above 50 DMA | Bullish | 4.84% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Up 5% | 1 day ago |
| Up 3% | 1 day ago |
| 60 Minute Opening Range Breakout | 1 day ago |
| Up 2% | 1 day ago |
| Rose Above Previous Day's High | 1 day ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/03/2021
INmune Bio, Inc. is a clinical-stage biotechnology company developing therapies targeting the innate immune system in cancer. INmune Bio is developing two products platforms that reengineer the patient’s innate immune system’s response to their cancer, INKmune and INB03. INKmune is a Natural Killer (NK) cell therapeutic that primes the patient’s NK cells to attack developing disease. INB03 inhibits myeloid derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors. INmune Bio’s product platforms target residual disease and utilize a precision medicine approach for treatment of a wide variety of hematologic malignancies and solid tumors.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Solid Tumors Immune System Immunotherapy Disease Cancer Treatments Precision Medicine Hematologic Malignancies Checkpoint Inhibitor Tumors Of The Hematopoietic And Lymphoid Tissues Mdsc Residual Disease
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Solid Tumors Immune System Immunotherapy Disease Cancer Treatments Precision Medicine Hematologic Malignancies Checkpoint Inhibitor Tumors Of The Hematopoietic And Lymphoid Tissues Mdsc Residual Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 30.37 |
| 52 Week Low | 7.28 |
| Average Volume | 531,924 |
| 200-Day Moving Average | 16.43 |
| 50-Day Moving Average | 18.90 |
| 20-Day Moving Average | 20.95 |
| 10-Day Moving Average | 18.53 |
| Average True Range | 2.09 |
| ADX | 16.81 |
| +DI | 26.10 |
| -DI | 23.42 |
| Chandelier Exit (Long, 3 ATRs) | 24.09 |
| Chandelier Exit (Short, 3 ATRs) | 23.10 |
| Upper Bollinger Bands | 27.02 |
| Lower Bollinger Band | 14.87 |
| Percent B (%b) | 0.43 |
| BandWidth | 58.00 |
| MACD Line | -0.13 |
| MACD Signal Line | 0.12 |
| MACD Histogram | -0.2481 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 22.95 | ||||
| Resistance 3 (R3) | 22.87 | 21.86 | 22.48 | ||
| Resistance 2 (R2) | 21.86 | 21.15 | 21.90 | 22.32 | |
| Resistance 1 (R1) | 21.00 | 20.70 | 21.43 | 21.08 | 22.17 |
| Pivot Point | 19.99 | 19.99 | 20.21 | 20.03 | 19.99 |
| Support 1 (S1) | 19.13 | 19.28 | 19.56 | 19.21 | 18.11 |
| Support 2 (S2) | 18.12 | 18.83 | 18.16 | 17.96 | |
| Support 3 (S3) | 17.26 | 18.12 | 17.80 | ||
| Support 4 (S4) | 17.34 |
